<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004221</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-204</org_study_id>
    <secondary_id>CTR20170071</secondary_id>
    <nct_id>NCT04004221</nct_id>
  </id_info>
  <brief_title>Study of BGB-A317 in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer</brief_title>
  <official_title>A Single-Arm, Multicenter Phase 2 Study of BGB-A317 in Patients With Previously Treated PD-L1+ Locally Advanced or Metastatic Urothelial Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the
      anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+,
      locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or
      following a platinum-containing regimen
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 4, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 3 Years, approximately</time_frame>
    <description>Defined as the proportion of participants who had confirmed complete response (CR) or partial response (PR) assessed by Independent Review Committee (IRC) using RECIST version 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 3 Years, approximately</time_frame>
    <description>Defined as the time from the first determination of a confirmed objective response by IRC according to RECIST version 1.1 until the first documentation of progression or death, whichever comes first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 3 Years, approximately</time_frame>
    <description>Defined as the time from the date of first dose of study drug to the date of first documentation of disease progression assessed by IRC using RECIST version 1.1 or death, whichever occurs first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 3 Years, approximately</time_frame>
    <description>Defined as the proportion of participants who achieve CR, PR and stable disease (SD) assessed by IRC using RECIST version 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 3 Years, approximately</time_frame>
    <description>Defined as the time from the date of first dose of study drug until the date of death from any cause</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Locally Advanced or Metastatic Urothelial Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>BGB-A317</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGB-A317 200mg intravenously (IV) every 3 weeks(Q3W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-A317</intervention_name>
    <description>BGB-A317 200mg intravenously (IV) every 3 weeks(Q3W)</description>
    <arm_group_label>BGB-A317</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Participants with histologically or cytologically documented locally advanced or
             metastatic transitional cell carcinoma (TCC) of the urothelium

          2. Disease progression during or following treatment with at least one
             platinum-containing regimen for inoperable locally advanced or metastatic urothelial
             carcinoma or disease recurrence

          3. Participants must submit archival tumor tissue for determination of program death
             ligand-1 (PD-L1) expression and other biomarker analyses. PD-L1 expression will be
             assessed centrally, and participants who are tested as PD-L1 high are eligible.

          4. Participants must have at least one measurable lesion as defined per RECIST version
             1.1 assessed by the investigator

          5. Male or female, aged ≥18 years on day of signing informed consent

          6. Participants have voluntarily agreed to participate by giving written informed consent

          7. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

          8. Life expectancy ≥12 weeks

          9. Participant must have adequate organ function as indicated by the following screening
             laboratory values obtained within 7 days prior to the first study treatment

               1. Absolute neutrophil count (ANC) ≥1.5×109/L

               2. Platelets ≥100×109/L

               3. Hemoglobin ≥9 g/dL or ≥5.6 mmol /L (Note: Criteria must be met without a
                  transfusion within 14 days of obtaining the sample)

               4. Calculated creatinine clearance ≥ 30 milliliter (mL)/min (Cockcroft-Gault
                  formula, see Appendix 5)

               5. Serum total bilirubin ≤ 1.5 X upper limit of normal (ULN) (total bilirubin must
                  be &lt;4 X ULN for participants with Gilbert's syndrome)

               6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 X ULN
                  OR ≤ 5 X ULN for participants with liver metastases

         10. Female participants are eligible to enter and participate in the study if they are of:

               1. Non-childbearing potential (ie, physiologically incapable of becoming pregnant),
                  including any female who i) Has had a hysterectomy ii) Has had a bilateral
                  oophorectomy (ovariectomy) iii) Has had a bilateral tubal ligation iv) Is post
                  menopausal (total cessation of menses for ≥1 year)

               2. Childbearing potential, has a negative serum pregnancy test at screening (within
                  7 days before the first investigational product administration), not be breast
                  feeding, and agree to remain abstinent (refrain from heterosexual intercourse) or
                  uses adequate contraceptive methods that result in a failure rate of &lt;1% per year
                  before study entry and throughout the study until 120 days after the last
                  investigational product administration

         11. Male participants are eligible to participate in the study if they are vasectomized or
             agree to use contraception during the study treatment period and for at least 120 days
             after the last dose of study drug

        Key Exclusion Criteria:

          1. History of severe hypersensitivity reactions to other humanized monoclonal antibodies

          2. Prior active malignancy within 2 years prior to Cycle 1 Day 1.

          3. Prior therapies targeting PD-1 or PD-L1.

          4. Active brain or leptomeningeal metastases as determined by computed tomography (CT) or
             magnetic resonance imaging (MRI) evaluation during screening and prior radiographic
             assessments.

          5. Participants with active autoimmune diseases or history of autoimmune diseases that
             may relapse should be excluded.

          6. Participants should be excluded if they have conditions requiring systemic treatment
             with either corticosteroids (&gt;10 mg daily prednisone equivalents) or other
             immunosuppressive medications within 14 days of study drug administration.

          7. Has history of interstitial lung disease or non-infectious pneumonitis except for
             those induced by radiation therapies

          8. With severe chronic or active infections (including tuberculosis infection, etc)
             requiring systemic antibacterial, antifungal or antiviral therapy within 14 days prior
             to first dose of study drug.

          9. With uncontrollable pleural effusion, pericardial effusion or ascites requiring
             pleurocentesis or abdominal tapping less than 4 weeks

         10. Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac
             disease (Class II or greater), myocardial infarction within the previous 3 months,
             unstable arrhythmias, or unstable angina

         11. Known history of Human Immunodeficiency Virus (HIV)

         12. Participants with untreated chronic hepatitis B or chronic hepatitis B virus (HBV)
             carrier with HBV deoxyribonucleic acid (DNA) ≥500 IU/mL (or 2.5 × 103 cps/mL), or
             active hepatitis C should be excluded. Participant with inactive hepatitis B surface
             antigen (HBsAg) carrier, active HBV infection with sustained anti-HBV suppression (HBV
             DNA &lt;500 IU/mL or 2.5 × 103 cps/mL) and participants whose hepatitis C has been cured
             (hepatitis C virus [HCV] ribonucleic acid [RNA] is lower than detection limit) can be
             enrolled

         13. Underlying medical conditions that, in the investigator's opinion, will make the
             administration of study drug hazardous or obscure the interpretation of toxicity
             determination or adverse events (AEs)

         14. Prior chemotherapy, radiotherapy, immunotherapy or any investigational therapies
             (including Chinese herbal medicine and Chinese patent medicines) used to control
             cancer within 2 weeks of Cycle 1 Day 1. AEs associated with these therapies must be
             Grade 0-1, baseline or stabilized (except for alopecia)

         15. Prior allogeneic stem cell or solid organ transplant

         16. Administration of a live or attenuated vaccine within 4 weeks prior to study drug
             administration

         17. Major surgical procedure other than for diagnosis within 28 days prior to study drug
             administration

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dingwei Ye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Hua Dong Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Soul</state>
        <zip>100021</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon request, and subject to certain criteria, conditions, and exceptions, BeiGene will provide access to individual de-identified participant data from BeiGene-sponsored global interventional clinical studies conducted for medicines for indications that have been approved or in programmes that have been terminated. BeiGene will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data requests can be submitted to medicalinformation@beigene.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

